MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00280-014-2384-1

Медицинская библиотека · Cancer chemotherapy and pharmacology · 2014

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Wheler Jennifer J, Janku Filip, Falchook Gerald S, Jackson Tiffiny L, Fu Siqing, Naing Aung, Tsimberidou Apostalia M, Moulder Stacy L, Hong David S, Yang Hui, Piha-Paul Sarina A, Atkins Johnique T, Garcia-Manero Guillermo, Kurzrock Razelle

Клиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

PURPOSE: Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

METHODS

Bevacizumab was administered at escalating dosages of 2.5-11 mg/kg on days 1 and 15, and oral valproic acid at dosages of 5.3-10 mg/kg on days 1-28 every 28 days to determine the maximum tolerated dose. Pharmacodynamic parameters were assessed in peripheral blood mononuclear cells (histone H3 acetylation) and serum (valproic acid levels).

RESULTS

Fifty-seven patients were enrolled. Dose-limiting toxicities were grade 3 altered mental status (n = 2), related to valproic acid. Bevacizumab 11 mg/kg given on days 1 and 15 and valproic acid 5.3 mg/kg daily were the recommended phase II dosages. Stable disease (SD) ≥6 months was reported in 4/57 (7 %) of patients, including two patients with colorectal cancer who had progressed previously on bevacizumab. Of the 39 patients evaluated for histone acetylation, 2 of 3 (67 %) patients with SD ≥6 months showed histone acetylation, while 8 of 36 (22 %) without SD ≥6 months demonstrated histone acetylation (p = 0.16). Patients with any grade of hypertension, compared to others, had a prolonged median survival (11.1 vs. 5.8 months; p = 0.012).

CONCLUSIONS

The combination of bevacizumab 11 mg/kg and valproic acid 5.3 mg/kg is safe in patients with advanced malignancies, with activity in colorectal, gastroesophageal junction, and prostate cancer. Patients with hypertension had improved overall survival.

Для цитирования: Wheler Jennifer J, Janku Filip, Falchook Gerald S, Jackson Tiffiny L, Fu Siqing, Naing Aung, Tsimberidou Apostalia M, Moulder Stacy L, Hong David S, Yang Hui, Piha-Paul Sarina A, Atkins Johnique T, Garcia-Manero Guillermo, Kurzrock Razelle. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.. Cancer chemotherapy and pharmacology. 2014. DOI: 10.1007/s00280-014-2384-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.